Imipenem‐cilastatin‐relebactam (IMI‐REL) is a novel β‐lactam–β‐lactamase inhibitor
combination recently approved for the treatment of complicated urinary tract infections …

Abstract Purpose of Review Resistant gram-negative infections are becoming increasingly
difficult to treat, prompting increased focus on drug development. This review will focus …

Abstract Purpose of Review Urinary tract infections (UTIs), including catheter-associated
UTIs, are among the most common bacterial infections in both inpatient and outpatient …

Background We conducted this study to describe the clinical characteristics, microbiology,
and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug …

Background. With increasing prevalence of vancomycin-resistant enterococci (VRE),
appropriate antibiotic therapy for enterococcal bloodstream infections (EBSI) can be …

Abstract Background Multidrug-resistant Pseudomonas aeruginosa infections remain
common in hospitals worldwide. We investigated the outcomes associated with the use of …

Vancomycin, a glycopeptide antimicrobial, is commonly employed for empirical and
definitive treatment of infections due to resistant gram-positive pathogens, notably methicillin …

Given the critical importance of early appropriate therapy, a retrospective cohort (2002 to
2013) was performed at the Detroit Medical Center to evaluate the association between the …

Background Urine cultures are nonspecific and often lead to misdiagnosis of urinary tract
infection and unnecessary antibiotics. Diagnostic stewardship is a set of procedures that …

Novel therapies for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream
infection (BSI) are needed in the setting of reduced antibiotic susceptibilities and therapeutic …